- Final Results
- Holding(s) in Company
- MRx0518 + Keytruda - Primary endpoint met in RCC
- Form F3 Registration Statement filed with SEC
- Participation in Chardan Microbiome Summit
- Parkinson’s trial receives FDA IND clearance
- Restatement of Interim Results to June 30, 2021
- Additional MRx04 Phase 1/2 asthma data and event
- 4D pharma to host virtual KOL event
- Participation in Upcoming Investor Conference
More ▼
Key statistics
On Friday, 4D Pharma PLC (DDDD:LSE) closed at 34.10, 39.38% above the 52 week low of 24.47 set on Mar 07, 2022.
52-week range
Markit short selling activity
Open | 34.75 |
---|---|
High | 34.90 |
Low | 32.45 |
Bid | 32.75 |
Offer | 59.00 |
Previous close | 34.10 |
Average volume | 1.84m |
---|---|
Shares outstanding | 180.30m |
Free float | 131.15m |
P/E (TTM) | -- |
Market cap | 62.83m GBP |
EPS (TTM) | -0.3361 GBP |
Data delayed at least 20 minutes, as of May 13 2022 16:35 BST.
More ▼
Investors Chronicle View
The last IC recommendation on 4D Pharma PLC shares was Sell at 127.50 on 24 Apr 2018Read the full article